Alan Nurden: Could Mast Cell aIIb Integrin Play a Key Role in Septic Thrombus Stability?
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Julie Rayes et al., published in Blood Advances, adding:
“Julie Rayes, Yuancheng Luo, Amit S Bhopal, Katharine Whitworth, Asif Jilani Iqbal, Alexander Brill; Mast cells enhance venous thrombus stability and lung fibrin deposition in murine sepsis.
This online manuscript from Birmingham, UK, provides much interesting data on how mast cells enhance venous thrombus stability and lung fibrin deposition in lipopolysaccharide-induced murine sepsis.
Enhanced neutrophil-induced trap formation was provoked by inflammatory mediators.
Ablation of mast cells resulted in thrombi comparable to those in control mice, furthermore their lysis was improved.
Lower angiopoietin levels suggested improved endothelial cell stability.
In the past, a Japanese group has shown that mast cells are able to synthesize appreciable quantities of alphaIIbbeta3 integrin (Oki T et al, J Immunol 2006; 176(1):52-60).
This historical finding has mostly stayed under the radar.
If it is indeed so, then maybe the integrin has a role to play in the processes described by Julie Rayes and her colleagues.
Going further, is it possible that patients with Glanzmann thrombasthenia are protected from the most severe effects of sepsis or indeed Covid-19. This could be worth investigating.”
Title: Mast cells enhance venous thrombus stability and lung fibrin deposition in murine sepsis
Authors: Julie Rayes, Yuancheng Luo, Amit S Bhopal, Katharine Whitworth, Asif Jilani Iqbal, Alexander Brill

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines